Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company, announced yesterday the appointment of Mark P. Carthy to the company’s Board of Directors. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened at $1.31 in last session, and closed at $1.42, while the day range of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock is $1.29 – $1.47. The stock showed a positive weekly performance of 27.93%.
US-based XOMA Corporation (NASDAQ:XOMA) has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for its IL-1 beta modulating antibody ‘gevokizumab’ for the treatment of pyoderma gangrenosum (PG). XOMA Corp (NASDAQ:XOMA) stock opened at $8.07 in last session, and closed at $8.91 by gaining 6.58%. The 52 week range of $2.62 – $9.53. Company’s market capitalization is $775.46M.
BioCryst Pharmaceuticals, Inc. logo Oppenheimer began coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note issued to investors on Friday, TheFlyOnTheWall.com reports. The firm issued a market perform rating on the stock. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock increased 6.16% and finished the last session at $12.41. The EPS of the stock remained -0.55. Company’s market capitalization is $733.32M.
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumours and the bone marrows of some hematologic malignancies (blood cancers) as treatments for patients living with cancer. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) stock opened the session at $5.19, and closed the session at $5.28. The 52 week range of the Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) stock remained $4.02 – $6.11 and the day range was $5.04 – $5.28.